PRINTER'S NO. 2395
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE RESOLUTION
No.
460
Session of
2019
INTRODUCED BY STRUZZI, SAPPEY, CONKLIN, READSHAW, RYAN,
SCHLOSSBERG AND SCHMITT, SEPTEMBER 3, 2019
REFERRED TO COMMITTEE ON HEALTH, SEPTEMBER 3, 2019
A RESOLUTION
Urging the United States Food and Drug Administration to
recognize this Commonwealth's concern with the safety of
kratom and the current distribution and sale of kratom as a
drug replacement, supplement or food and to promptly consider
guidelines and protocols for the safe use of kratom.
WHEREAS, The United States Food and Drug Administration (FDA)
has issued warnings to consumers to not use Mitragyna speciosa,
commonly known as kratom, a plant which grows naturally in
Thailand, Malaysia, Indonesia and Papua New Guinea, because the
plant affects the same opioid brain receptors as morphine and
appears to have properties that expose users to the risks of
addiction, abuse and dependence; and
WHEREAS, Kratom is consumed by chewing the leaves, drying and
smoking the leaves, putting the leaves into capsules or tablets
or boiling the leaves into a tea; and
WHEREAS, The effects from kratom are unique in that
stimulation occurs at low doses and opioid-like depressant and
euphoric effects occur at higher doses; and
WHEREAS, The FDA has issued reports about deaths associated
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19